Eyepoint Pharmaceuticals Pivots to Diabetic Macular Edema After Trial Setbacks

Eyepoint Pharmaceuticals (NASDAQ:EYPT) is focusing its lead drug candidate, DURAVYU, on diabetic macular edema after two late-stage trials in wet age-related macular degeneration missed their primary endpoints, CEO Jay Duker said at the Jefferies Global Healthcare Conference in London.

The company is closing the wet AMD trials, known as LUGANO and LUCIA, and is pursuing diabetic macular edema, or DME, for the time being. Duker said secondary measures in the wet AMD studies, including safety and fluid control, supported continued development in DME, although the drug did not meet the trials’ primary goals.

DURAVYU combines vorolanib, a small-molecule tyrosine kinase inhibitor, with EyePoint’s sustained-release delivery system. Duker said the system delivers the drug through an injection into the eye and lasts at least six months or longer in almost all patients.

DME Confidence Rests on Small Phase 2 Study

Duker said DME and wet AMD have different underlying disease processes, with inflammation playing a role in DME. He cited preclinical evidence that vorolanib has an anti-inflammatory effect, as well as results from EyePoint’s Phase 2 VERONA study.

At 24 weeks in VERONA, DURAVYU was non-inferior to EYLEA 2 mg on vision outcomes, with both groups gaining about seven letters, Duker said. He added that fluid control was better in the DURAVYU group and that patients receiving the drug had better vision and less retinal fluid as early as week four.

The trial was small: 11 eyes were randomized to the higher DURAVYU dose, 10 to the lower dose and six to the control group. Duker acknowledged the sample size but said the consistency between vision improvements and reductions in fluid gave him confidence in the results.

All eyes in VERONA received an initial EYLEA injection, followed 30 minutes later by either DURAVYU or a sham procedure. More than 70% of eyes treated with DURAVYU completed the trial without additional injections, Duker said.

Late-Stage Program and Cash Position

EyePoint has two Phase 3 DME trials. Duker said the program was fully enrolled and that the company was not planning an early futility analysis. He also said the criteria for supplemental treatment had been tightened compared with the earlier approach.

Executives gave differing timing references for data. Duker said the DME trial should read out early in the first quarter of next year. CFO George Elston later said the company had updated its guidance to early in the fourth quarter of 2027. The discrepancy was not resolved during the discussion.

Elston said EyePoint ended September with $118 million in cash. Following the LUCIA results, the company announced a reorganization that reduced headcount by more than 53%. He said EyePoint was reviewing spending to extend its cash through the data readout while maintaining clinical-trial operations and its manufacturing facility for a potential DME application.

Asked when investors could expect another runway update, Elston said the company was evaluating a range of plans and pointed to the new year for a further update.

About Eyepoint Pharmaceuticals (NASDAQ:EYPT)

EyePoint Pharmaceuticals is a biopharmaceutical company focused on developing treatments for serious eye diseases. Its drug-delivery technology is designed to provide sustained release of medication in the eye, with the goal of reducing the need for frequent injections or other repeated treatments. The company’s pipeline includes DURAVYU, an investigational sustained-release treatment being studied for retinal conditions including wet age-related macular degeneration and diabetic retinopathy. EyePoint previously developed and marketed ophthalmic products including YUTIQ and DEXYCU, and sold those commercial assets to Alimera Sciences in 2023.